CN Stock MarketDetailed Quotes

688176 Jiangsu Yahong Meditech

Watchlist
  • 8.06
  • -0.03-0.37%
Market Closed Nov 7 15:00 CST
4.59BMarket Cap-11400P/E (TTM)

About Jiangsu Yahong Meditech Company

The company is a company limited by the overall restructuring of the former Jiangsu Yahong Pharmaceutical Technology Co., Ltd., and was registered with the approval of the Jiangsu Taizhou Administration for Industry and Commerce on March 16, 2010. The company's shares were listed and traded on the Shanghai Stock Exchange on January 7, 2022. The company is a global specialty innovative pharmaceutical company focusing on urogenital tumors and other major diseases. It is a leading international pharmaceutical company integrating R&D, production and sales in the field of treatment, providing the best integrated diagnosis and treatment solutions for patients in China and around the world. Main products: APL-1702, APL-1706, APL-1202, APL-1501, APLD-2304, AT-014, AT-020,, APL-2302, AT-017,, AT-018,,. AT-021 APL-1202 APL-1401 APL-2301

Company Profile

Short Name-A亚虹医药科技
Company NameJiangsu Yahong Meditech Co., Ltd.
Listing DateJan 7, 2022
Issue Price22.98
Shares Offered110.00M share(s)
FoundedMar 16, 2010
ChairmanPAN KE
Legal RepresentativePAN KE
General ManagerPAN KE
Secretarymingyuan yang
Employees394
ProvinceJiang Su Sheng
Phone021-68583836
Office Address19F, Building B, Qiantan World Trade Center (Phase III), Lane 221, Dongyu Road, Pudong, Shanghai
Zip Code200126
Registered AddressRoom 1009, Building D, Phase II, New Drug Creation Base, No. 1, Yaocheng Avenue (east side of Chuangye Road and north side of Yuannan Road), Taizhou, Jiangsu
Fax021-68585281
Emailsecurities@asieris.cn
Business License91321291552450798T
BusinessThe issuer is a global innovative pharmaceutical company focusing on urogenitalSystem (UroGenitalSystem) tumors and other major diseases. Adhering to the corporate mission of “improving human health and making life more dignified”, the issuer aspires to become a leading international pharmaceutical company integrating R&D, production and commercialization in the field of treatment, providing the best integrated diagnosis and treatment solutions for patients in China and around the world.

Company Executives

  • Name
  • Position
  • Salary
  • PAN KE
  • Chairman, Directors, General Manager, Core Technical Personnel
  • --
  • ZHUANG CHENGFENG JOHN
  • Directors, Deputy General Manager
  • 2.40M
  • xinming jiang
  • Directors
  • 1.78M
  • wende chen
  • Directors
  • --
  • binghui zhang
  • Independent Directors
  • 150.00K
  • wenning wang
  • Independent Directors
  • --
  • bin huang
  • Independent Directors
  • 150.00K
  • yi zhong
  • Chairman of the Supervisory Board, Employee Representative Supervisor
  • 876.40K
  • jiani kang
  • Auditors
  • --
  • runlei zhang
  • Auditors
  • --
  • mingyuan yang
  • Head of Finance
  • --
  • YIJUN DENG
  • Core Technical Personnel
  • --
  • YUSHEN GUO
  • Core Technical Personnel
  • --
  • jianghua liu
  • Core Technical Personnel
  • --
  • liang wu
  • Core Technical Personnel
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data